Mechanisms and issues relating to the use of D1-like dopamine receptor agonists for age-related illnesses: Parkinson's disease and memory and cognition

David E. Nichols, Mechelle M. Lewis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Parkinson's disease is the second most common age related neurodegenerative disorder that, along with age-related declines in memory and cognition, represents an area of medicine in which there have not been major advances in decades. This paper will focus on the great potential that D1-like dopamine agonists may have in these arenas. Although levodopa has been the most effective treatment for Parkinson's disease (PD), pharmacokinetic and bioconversion problems have led to efforts to develop direct acting dopamine agonists for PD. Although the large majority of research and development has been focused on D2-like direct agonists, this talk will show data illustrating why D1 agonists should be a high priority pharmacotherapeutic target for treatment of PD. This presentation will review the neurobiological and molecular pharmacological evidence that supports this hypothesis, some of the scientific hurdles, and the current state of the medicinal chemistry of D1 agonist development. The concluding portion of the talk will review the experimental evidence suggesting that D 1-like agonists can lead to improvements in memory and cognitive function, and review the current status of drug discovery and development for these uses.

Original languageEnglish (US)
Pages (from-to)105-114
Number of pages10
JournalMedicinal Chemistry Research
Volume13
Issue number1-2
DOIs
StatePublished - Nov 8 2004

Fingerprint

Dopamine Agonists
Cognition
Parkinson Disease
Data storage equipment
Bioconversion
Pharmacokinetics
Pharmaceutical Chemistry
Levodopa
Drug Discovery
Neurodegenerative Diseases
Medicine
Pharmacology
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

@article{67888e41cdd943e29adc547005d764b1,
title = "Mechanisms and issues relating to the use of D1-like dopamine receptor agonists for age-related illnesses: Parkinson's disease and memory and cognition",
abstract = "Parkinson's disease is the second most common age related neurodegenerative disorder that, along with age-related declines in memory and cognition, represents an area of medicine in which there have not been major advances in decades. This paper will focus on the great potential that D1-like dopamine agonists may have in these arenas. Although levodopa has been the most effective treatment for Parkinson's disease (PD), pharmacokinetic and bioconversion problems have led to efforts to develop direct acting dopamine agonists for PD. Although the large majority of research and development has been focused on D2-like direct agonists, this talk will show data illustrating why D1 agonists should be a high priority pharmacotherapeutic target for treatment of PD. This presentation will review the neurobiological and molecular pharmacological evidence that supports this hypothesis, some of the scientific hurdles, and the current state of the medicinal chemistry of D1 agonist development. The concluding portion of the talk will review the experimental evidence suggesting that D 1-like agonists can lead to improvements in memory and cognitive function, and review the current status of drug discovery and development for these uses.",
author = "Nichols, {David E.} and Lewis, {Mechelle M.}",
year = "2004",
month = "11",
day = "8",
doi = "10.1007/s00044-004-0016-8",
language = "English (US)",
volume = "13",
pages = "105--114",
journal = "Medicinal Chemistry Research",
issn = "1054-2523",
publisher = "Birkhause Boston",
number = "1-2",

}

TY - JOUR

T1 - Mechanisms and issues relating to the use of D1-like dopamine receptor agonists for age-related illnesses

T2 - Parkinson's disease and memory and cognition

AU - Nichols, David E.

AU - Lewis, Mechelle M.

PY - 2004/11/8

Y1 - 2004/11/8

N2 - Parkinson's disease is the second most common age related neurodegenerative disorder that, along with age-related declines in memory and cognition, represents an area of medicine in which there have not been major advances in decades. This paper will focus on the great potential that D1-like dopamine agonists may have in these arenas. Although levodopa has been the most effective treatment for Parkinson's disease (PD), pharmacokinetic and bioconversion problems have led to efforts to develop direct acting dopamine agonists for PD. Although the large majority of research and development has been focused on D2-like direct agonists, this talk will show data illustrating why D1 agonists should be a high priority pharmacotherapeutic target for treatment of PD. This presentation will review the neurobiological and molecular pharmacological evidence that supports this hypothesis, some of the scientific hurdles, and the current state of the medicinal chemistry of D1 agonist development. The concluding portion of the talk will review the experimental evidence suggesting that D 1-like agonists can lead to improvements in memory and cognitive function, and review the current status of drug discovery and development for these uses.

AB - Parkinson's disease is the second most common age related neurodegenerative disorder that, along with age-related declines in memory and cognition, represents an area of medicine in which there have not been major advances in decades. This paper will focus on the great potential that D1-like dopamine agonists may have in these arenas. Although levodopa has been the most effective treatment for Parkinson's disease (PD), pharmacokinetic and bioconversion problems have led to efforts to develop direct acting dopamine agonists for PD. Although the large majority of research and development has been focused on D2-like direct agonists, this talk will show data illustrating why D1 agonists should be a high priority pharmacotherapeutic target for treatment of PD. This presentation will review the neurobiological and molecular pharmacological evidence that supports this hypothesis, some of the scientific hurdles, and the current state of the medicinal chemistry of D1 agonist development. The concluding portion of the talk will review the experimental evidence suggesting that D 1-like agonists can lead to improvements in memory and cognitive function, and review the current status of drug discovery and development for these uses.

UR - http://www.scopus.com/inward/record.url?scp=7044248192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044248192&partnerID=8YFLogxK

U2 - 10.1007/s00044-004-0016-8

DO - 10.1007/s00044-004-0016-8

M3 - Article

AN - SCOPUS:7044248192

VL - 13

SP - 105

EP - 114

JO - Medicinal Chemistry Research

JF - Medicinal Chemistry Research

SN - 1054-2523

IS - 1-2

ER -